Lilly Announces an Extension to 2015 Research Collaboration deal with Dana Farber Cancer Institute
Lilly Announces an Extension to 2015 Research Collaboration deal with Dana Farber Cancer Institute
Shots:
- The extension provides a better understanding to clinicians and initial funding discoveries, molecular analyses, design and conduct of samples for new discoveries in cancer
- Agreement defines that Dana has right to perform multiple clinical and preclinical trials adding in Lilly’s pipeline
- Evaluated compound ownership will remain under Lilly